REVIEW article
Front. Nutr.
Sec. Nutrition and Microbes
Bioactive Components and Delivery Strategies of Food-Medicine Homologous Substances in Lung Cancer Therapy: Current Advances and Clinical Translation
Provisionally accepted
- Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer remains the leading cause of cancer-related mortality worldwide, challenged by drug resistance, treatment toxicities, and limited efficacy. Recently, food-medicine homologous (FMH) substances have gained attention as adjunctive therapies due to their multi-target effects, low toxicity, and favorable safety profiles. As the "food as medicine" paradigm integrates into health policies, a comprehensive understanding of FMH in lung cancer therapy as a form of nutrition-based adjuvant therapy is increasingly relevant and timely. This review summarizes the anti-lung cancer mechanisms of FMH-derived bioactive compounds—such as polysaccharides, saponins, polyphenols, alkaloids, and essential oils—focusing on their roles in cell cycle regulation, apoptosis induction, immune modulation, and resistance reversal. To address poor bioavailability, we highlight recent advances in nanodelivery systems that enhance therapeutic efficacy. Moreover, we examine nutritional modulation of gut microbiota under the gut–lung axis framework as a novel strategy in lung cancer treatment. By integrating preclinical evidence with translational studies, this review evaluates the clinical potential and future directions of FMH-based therapies. The aim is to provide a theoretical basis for optimizing integrative Chinese–Western approaches and advancing personalized nutrition-oriented strategies in lung cancer care.
Keywords: Food-Medicine Homologous, Nutritional intervention, lung cancer, gut–lung axis, nanocarriers, review
Received: 31 Aug 2025; Accepted: 27 Nov 2025.
Copyright: © 2025 Sun, Zang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jun Chen
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.